IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 8, May 2026
Impact Factor: 8.2

Antidrug Response through Deep Learning Analysis of Genetic Data

Prof. Vikas Gaikwad[1], Kunal Khairnar[2], Prathamesh Patil[3], Anuj Dandavate[4], Prashasti Lokhande[5]
Professor, Department of Artificial Intelligence & Data Science Engineering[1]
Students, Department of Artificial Intelligence & Data Science Engineering[2-5]
Shree Ramchandra College of Engineering, Pune, Maharashtra, India

Abstract: *Accurate prediction of ADR remains a critical challenge in personalized medicine due to great genetic heterogeneity among patients. This review provides an overview of current deep learning methodologies that have been designed for the task of predicting ADR using genetic sequencing. We review recent literature on a key trend: the transition away from single-omics analyses and into integrated multi-omics approaches to create a comprehensive patient profile. Furthermore, we analyze more complex models-many state-of-the-art hybrid graph convolutional networks-that automatically learn latent representations of drug chemical structures beyond the limitations of hand-crafted features. This paper points out that these models, very often combined with 1D CNNs, are achieving state-of-the-art results and allowing the research area to move well beyond its initial narrow focus on oncology. The results confirm that deep learning with multi-omics data plays an important role in advancing precise, personalized recommendations of drugs and improving therapeutic outcomes*

Keywords: Anti-Drug Response (ADR), Deep Learning, Genetic Sequencing, Multi-omics, Graph Convolutional Networks (GCNs)

I. INTRODUCTION

Personalized medicine represents a paradigm shift from a "one-size-fits-all" treatment model to tailored therapeutic strategies optimized for the individual. The cornerstone for this has been pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs. With the substantial progress against the application of personalized medicine, an obstacle remains with the high variability in patient response to therapies, including the occurrence of adverse drug responses. Predicting whether a patient will respond favorably to a drug or experience a harmful reaction is critical to enhanced therapeutic efficacy, reduced toxicity, and less time and cost associated with trial-and-error treatment approaches. This variability is deeply rooted in the complex interplay between a drug's properties and the unique biological profile of a patient. This profile is not defined by genomics alone. The advent of high-throughput sequencing has provided unprecedented insight into patient biology through multi-omics data, encompassing genomics (DNA mutations), transcriptomics (RNA expression), and epigenomics (modifications regulating gene expression). Historically, computational models for ADR prediction struggled with this complexity. Early network-driven models, which relied on drug-drug or cell-line similarities, often faced scalability issues and failed to capture the intricate details of patient heterogeneity. Furthermore, classical machine learning models suffered from two major limitations. The first was a reliance on hand-crafted features to represent drugs, which often missed capturing the intrinsic topological and chemical structures that truly drive the mechanism of action of a drug. Second, most studies focused on only one type of omics data, such as genomics, and missed the rich, synergistic information provided by integrating multiple omics layers.

II. PROBLEM STATEMENT

To design and implement a deep learning–based system that leverages patient genetic data to predict drug response in advance and recommend the most effective drug, thereby minimizing side effects and improving treatment accuracy.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 8, May 2026
Impact Factor: 8.2

III. OBJECTIVES

• Analyze limitations of traditional ADR prediction models, focusing on scalability issues and reliance on handcrafted features.
• Survey the current landscape of deep learning methods that use genetic and multi-omics data for anti-drug response prediction.
• Evaluate studies using Graph Convolutional Networks (GCNs) to automatically learn feature representations from drug molecular structures.
• Investigate the effectiveness of integrating diverse multi-omics profiles (genomics, transcriptomics) in hybrid deep learning frameworks.
• Identify key challenges and future directions for developing robust, clinically viable ADR prediction models beyond just oncology.

IV. SCOPE

Doctors & Clinicians: Utilize the system to receive personalized drug response predictions, moving beyond "trial-and-error" prescribing.
Pharmaceutical Companies: Employ the model during drug development to better understand response heterogeneity and screen potential compounds.
Clinical Researchers: Use the platform to analyze multi-omic data, identify new biomarkers, and inform studies on drug resistance.
The core of the system is a hybrid deep learning model. This model is capable of integrating complex, high dimensional patient data, including multi-omics profiles (genomics, transcriptomics) and the intrinsic chemical structures of drugs. It learns patterns from this data to predict drug efficacy and potential adverse responses.

V. LITERATURE SURVEY

Sr. No	Title	Author	Year	Description
1.	DeepDSC: A Deep Learning Method to Predict Drug Sensitivity of Cell Line	Min Li, Yake Wang, Ruiqing Zheng, Xinghua Shi, Yaohang Li, Fang-Xiang Wu, and Jianxin Wang	2021	he proposed system integrated both genomic features of cell lines and chemical information of compounds to predict the half maximal inhibitory concentrations using a deep neural network.
2.	Prediction of Cancer Drug Effectiveness Based on Multi-Fusion Deep Learning Mode	Qian Li, Jie Huang, HongMing Zhu	2020	It provides a new method fo po response prediction and provides some guidance for the screening of effective anti drugs.
3.	DeepCDR: A Hybrid Graph Convolutional Network for Prediction of Cancer Drug Response	Qiao Liu, Zhiqiang Hu, Rui Jiang, and Mu Zhou.	2020	The proposed system developed DeepCDR, which integrates multi-omics profiles of cancer cells and explores intrinsic chemical structures of drugs for predicting CDR.
4.	Deep Learning for Drug Response Prediction in Cancer	Delora Baptista, Pedro G. Ferreira, and Miguel Rocha	2020	Deep Learning for Drug Response Prediction in Cancer.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 8, May 2026
Impact Factor: 8.2

VI. METHODOLOGY

The literature on anti-drug response prediction evidences a very clear evolution, from traditional machine learning to more sophisticated deep learning architectures. A variety of models, classified into feature representation and data-integrating strategies, were analyzed in the review.

1. Traditional Machine Learning and Early DL Models: Initial computational approaches often relied on conventional machine learning algorithms, such as Random Forests and Support Vector Machines, applied to hand-crafted features. This means for drugs, molecular fingerprints or physicochemical properties; for patients, it typically means the use of curated gene expression signatures. While foundational, these models struggle to capture the full complexity of high-dimensional data. Early deep learning models, including basic Multi-Layer Perceptrons and 1D Convolutional Neural Networks, improved upon this by learning features from flattened genomics data but still commonly used simplified drug representations.

2. Hybrid Deep Learning Architectures: The current state-of-the-art, and the primary focus of this analysis, includes hybrid deep learning frameworks that represent patient and drug information using separate, specialized subnetworks. A common architecture, as in the models DeepADR, for example, consists of two major branches: Drug Representation (Graph Convolutional Networks): A significant development here has been the move from representation based on features to structural representation of drugs. This innovation used graph convolutional networks, which directly operate on the 2D or 3D molecular graph of a drug. This lets the model learn complex and hierarchical features related to the topological structure and atomic bonds of the drug in an entirely data-driven manner, bypassing the need for explicit feature engineering.



VII. MODELING AND ANALYSIS

1. Data Acquisition This first step involves gathering two key datasets for each individual: their clinical/medical history and their biological genome samples (like DNA or RNA).

2. Data Preparation and Refinement All the raw data is cleaned to remove errors and normalized to a uniform standard. This "clean-up" phase ensures the data is consistent and accurate before being used.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 8, May 2026
Impact Factor: 8.2

3. Data Integration The two clean datasets (medical history and genetic data) are combined into one single, unified file. This gives the model a complete picture by linking each patient's genetics to their medical profile.
4. Machine Learning Model Training The integrated dataset is fed into the deep learning model. The model learns to find complex patterns and associations between specific genetic markers and drug responses.
5. Model Validation The trained model is tested against new, unseen patient data to check its accuracy. This "quality check" ensures the model's predictions are reliable and can be trusted.
6. Prediction and Recommendation A new patient's data is fed into the validated model. The model then generates a personalized prediction ("Sensitive" or "Resistant") and recommends the most effective drugs.
7. Clinical Decision Support These predictions are given to doctors as a "decision support tool." This allows the doctor to combine their expertise with the model's genetic insights to choose the best treatment.
8. Monitoring and Feedback After treatment, the patient's real-world results are collected and fed back into the system. This continuous feedback loop helps to retrain and improve the model, making it smarter over time.

VIII. SYSTEM ARCHITECTURE



DOI: 10.48175/IJARSCT-35543

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 8, May 2026
Impact Factor: 8.2

IX. RESULT AND DISCUSSION





DOI: 10.48175/IJARSCT-35543

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 8, May 2026
Impact Factor: 8.2



X. CONCLUSION

This project successfully demonstrates how Deep Learning and genetic analysis can be used to predict anti-drug response more accurately. By combining multi-omics patient data with drug chemical structures, the system predicts whether a drug will be Sensitive or Resistant for a patient. The proposed model helps reduce trial-and-error treatment, minimizes side effects, and supports personalized medicine. It also improves healthcare decision-making through AI-based predictions and smart analysis. Overall, the project represents an important step toward intelligent and precision-based healthcare systems.

XI. ACKNOWLEDGEMENTS

We express our heartfelt gratitude to Prof. Vikas Gaikwad for his guidance, valuable insights, and continuous encouragement during the project. We thank the Department of Artificial Intelligence and Data Science, Shree Ramchandra College of Engineering, Pune, for providing the necessary support and resources. Lastly, we are grateful to our friends for their motivation throughout this journey.

REFERENCES

[1] M. Kato, A. Emad, D.-H. Le, et al., "Deep learning methods for drug response prediction in genome sickness: Predominant and emerging trends," Briefings in Bioinformatics, Vol. 22, Issue 3, 2023, pp. 1429-1443.
[2] Y. Wang, T. Liu, C. Zhang, J. Xu, and Y. Wang, "DeepDSC: A Deep Learning Method to Predict Drug Sensitivity of Genome sickness Cell Lines," Frontiers in Genetics, Vol. 10, No. 1117, 2021.
[3] Q. Li and J. Huang, "Prediction of Anti drug Effectiveness Based on Multi-Fusion Deep Learning Model," IEEE Access, Vol. 9, 2021.
[4] D. Baptista, P. Ferreira, and M. Rocha, "Deep learning for drug response prediction in genome sickness," Briefings in Bioinformatics, 2020.
[5] Q. Liu, Z. Hu, R. Jiang, and M. Zhou, "DeepADR: a hybrid graph convolutional network for predicting anti-drug response," Bioinformatics, 2020